Document:

<PAGE>
                                                                    EXHIBIT 10.2

                                                                  April 21, 2005

Mr. Michael Atieh
10 Longwood Road
Morristown, NJ 07920

Re: Employment Agreement

Dear Mike:

     This letter is to confirm our understanding with respect to (i) your future
employment by OSI Pharmaceuticals, Inc. (the "Company"), (ii) your agreement not
to solicit employees or customers of the Company, or any present or future
parent, subsidiary or affiliate of the Company (each, a "Company Affiliate" and
collectively, together with the Company, the "Company", (iii) your agreement to
protect and preserve information and property which is confidential and
proprietary to the Company, and (iv) your agreement with respect to the
ownership of inventions, ideas, copyrights and patents which may be used in the
business of the Company (the terms and conditions agreed to in this letter are
hereinafter referred to as the "Agreement"). In consideration of the mutual
promises and covenants contained in this Agreement, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby mutually
acknowledged, we have agreed as follows:

     1. Employment.

          (a) Subject to the terms and conditions of this Agreement, the Company
     will employ you, and you will be employed by the Company and/or any Company
     Affiliate designated by the Company, initially as Executive Vice President
     and Chief Financial Officer, of the Company reporting to the Chief
     Executive Officer (the "CEO") of the Company. You will have the
     responsibilities, duties and authority customarily performed, undertaken
     and exercised by a person in a similar executive capacity. You will also
     perform such other and/or different services for the Company as may be
     assigned to you from time to time by the CEO. The principal location at
     which you will perform such services will be the Company's headquarters
     located at 58 South Service Road, Melville, New York, although you will be
     available to perform services at any other Company facility and to travel
     as the needs of business may require.

          (b) Devotion to Duties. While you are employed hereunder, you will, to
     the best of your ability, perform faithfully and diligently all duties
     assigned to you pursuant to this Agreement and will devote your full
     business time and energies to the business
<PAGE>
     and affairs of the Company. While you are employed hereunder, you will not
     undertake any other employment from any person or entity without the prior
     written consent of the Company.

     2. Term. Except for earlier termination as provided for in Section 4
     hereof, your employment under this Agreement (the "Employment Term") shall
     be for an initial term commencing on May 31, 2005 (the "Effective Date")
     and ending on the third anniversary of the Effective Date (the "Initial
     Term"). Unless written notice is given of an intent not to extend the
     Initial Term or any extension thereof by you or the Company at least 90
     days prior to an anniversary of the Effective Date, the Employment Term
     shall be deemed, as of such 90th day, to have been extended and continue
     until the end of the successive 12-month period unless otherwise terminated
     as provided for in Section 4 hereof. In the event the Company elects not to
     renew the Employment Term, you shall be entitled to the payments and
     benefits set forth in Section 6(c).

     3. Compensation.

          (a) Base Salary. While you are employed hereunder, the Company will
     pay you a base salary at the annual rate of $410,000 (the "Base Salary").
     Your Base Salary will be reviewed on an annual basis each January (or such
     other time as determined by the CEO and/or the Compensation Committee of
     the Board of Directors of the Company (the "Board")), commencing with
     January, 2006. The Base Salary will be payable in equal installments in
     accordance with the Company's payroll practices as in effect from time to
     time. The Company will deduct from each such installment all amounts
     required to be deducted or withheld under applicable law or under any
     employee benefit plan in which you participate.

          (b) Bonus. In addition to the Base Salary, for each fiscal year of the
     Company ending during the Term of the Agreement, beginning with the 2005
     fiscal year, you will be eligible to receive a target bonus of between
     $200,000 - $300,000, determined and payable in accordance with the
     Company's practices applicable to bonuses paid to its executives. The
     Company's bonus system is a discretionary annual performance-based
     incentive bonus system, approved by the Company's Board, and is based upon
     a combination of personal and corporate performance contributing to your
     maximum target. Bonuses are determined in December of each year.

          (c) Equity Compensation.

               (i) Initial Grant. On the Effective Date and pursuant to a
          written stock option agreement (the "Stock Option Agreement") between
          the Company and you under the OSI Pharmaceuticals, Inc. Amended and
          Restated Stock Incentive Plan (the "Plan"), you will be granted a
          non-qualified option (the "Initial Option") to purchase 150,000 shares
          of the Company's common stock, par value, $.01 per share (the "Common
          Stock"). The exercise price will be determined based on the fair
          market value determined at the close of business on the first business
          day of the month after your employment begins. The Initial

                                        2
<PAGE>
          Option will have a term of 10 years and will become exercisable with
          respect to 33% of such shares on the first anniversary of the date of
          grant with the remaining shares vesting over the succeeding 48 months
          following the first anniversary of the date of grant on a monthly
          pro-rated basis. Notwithstanding the foregoing, the Initial Option
          shall vest and be fully exercisable upon a Change of Control (as
          hereinafter defined).

               (ii) Future Grants. On each date that annual stock options or
          other equity compensation are granted by the Company to its executive
          management group, so long as you then remain in the employ of the
          Company, the Company will grant to you an option (an "Annual Option")
          to purchase a number of shares of Common Stock to be determined by the
          Compensation Committee of the Board based upon your grade level. The
          exercise price for each Annual Option will be the fair market value
          per share of Common Stock on the date the Annual Option is granted and
          the other terms and conditions of the Annual Option will be as set
          forth in the Plan and Option Agreement accompanying such Annual
          Option. Each Annual Option will have a term of 10 years and will
          become exercisable with respect to 33% of such shares on the first
          anniversary of the date of grant with the remaining shares vesting
          over the succeeding 24 months following the first anniversary of the
          date of grant on a monthly pro-rated basis. Notwithstanding the
          foregoing, each Annual Option shall vest and be fully exercisable upon
          a Change of Control (as hereinafter defined).

               (iii) Restricted Stock Grant On the first business day of the
          month after your employment begins you will be granted a restricted
          stock grant of 15, 000 shares at the closing price of the stock on
          such date. The restrictions will lift on an annual basis at twenty
          percent per year over a period of five years. Notwithstanding the
          foregoing, the Restricted Stock Grant shall vest and be fully
          exercisable upon a Change of Control (as hereinafter defined).

          (d) Vacation. You will be entitled to 22 paid vacation days in each
     calendar year, and paid holidays plus personal days in accordance with the
     Company's policies for its senior executives as in effect from time to
     time.

          (e) Fringe Benefits. In addition to the equity compensation provided
     for herein, you will be entitled to participate in employee benefit plans
     which the Company provides or may establish for the benefit of its senior
     executives generally (for example, term life, disability, medical, dental
     and other insurance, retirement, pension, profit-sharing and similar plans)
     (collectively, the "Fringe Benefits"). Your eligibility to participate in
     the Fringe Benefits and receive benefits thereunder will be subject to the
     plan documents governing such Fringe Benefits. Nothing contained herein
     will require the Company to establish or maintain any Fringe Benefits.

          (f) Relocation. The Company will assist you in your relocation to Long
     Island in accordance with the following:

                                        3
<PAGE>
               (i) Relocation Service. American International will assist you in
          your relocation from New Jersey to Long Island.

               (ii) Current Residence. The Company, through American
          International and at your request, will appraise your current
          residence in New Jersey. You will market your home with their
          assistance to try to find a third-party buyer. If the sale price is
          less than the averaged appraisals, OSI will reimburse you the
          difference.

               (iii) Expenses. The Company will reimburse you, either directly
          or through its relocation service, American International, for all
          expenses relating to your relocation from New Jersey to Long Island,
          including, without limitation, expenses relating to packing and moving
          household goods, temporary storage of household goods, closing costs
          (including 2 mortgage points) associated with the purchase of a new
          home on Long Island, sales and closing costs associated with the sale
          of your home in New Jersey, expenses incurred by you and/or your
          family relating to house-hunting trips (including transportation,
          hotel accommodations and meals) and expenses incurred by you and/or
          your family for temporary living accommodations for up to six months
          prior to your move into a new home (including transportation, lease or
          sublease amounts, utilities, hotel or other accommodations, brokers'
          fees). During this 6 month period The Company will pay for a car
          service to bring you to and from Long Island on Mondays and Fridays.
          The Company will continue to pay for your living costs and for a car
          service after the six month period, but any such costs will be fully
          recaptured versus your final relocation costs.

               (iv) Mortgage Assistance. For a period of three years following
          your purchase of a home on Long Island (the "Long Island Home"), the
          Company will pay you a mortgage assistance allowance equal to $50,000
          per annum, payable in equal monthly installments. The foregoing is
          subject to your continued employment with the Company during such
          three-year period. If (A) your employment terminates "without cause"
          (as defined in Section 4(e) hereof), (B) you terminate your employment
          for "good reason" (as defined in Section 4(d) hereof), or (C) upon a
          "Change of Control" (as defined in Section 7 hereof) prior to the end
          of such three-year period, you will continue to receive such mortgage
          assistance allowance on the terms described in this section provided
          that you remain resident in the Long Island Home.

               (v) Lump Sum Payment. In addition to the amounts provided for in
          Sections 3 (f) (iii) and (iv), upon your purchase of the Long Island
          Home, you will receive a one-time lump sum payment equal to $25,000 to
          cover incidental expenses.

               (vii) Pay-Back. If, within 12 months following the Effective
          Date, you terminate your employment with the Company "without good
          reason" (as defined in Section 4(f) hereof), you shall pay back all
          (based upon the date of your termination) of

                                        4
<PAGE>
          the amounts paid to you pursuant to Sections 3 (f) (iii), (iv), (v)
          and (vi) (the "Relocation Expenses").

               (viii) Documentation. Reimbursement of the expenses provided for
          in this Section 3(f) shall be made upon presentation of documentation
          reasonably satisfactory to the Company in accordance with the
          Company's policies with respect thereto as in effect from time to
          time. Receipts shall not be required for payment covered under Section
          3 (f) (v).

               (ix) Any amounts paid under this Section 3 (f) deemed to be
          taxable income to you will be grossed up for taxes at the appropriate
          rate.

          (g) Reimbursement of Expenses. Upon presentation of documentation of
     such expenses reasonably satisfactory to the Company, the Company will
     reimburse you for all ordinary and reasonable out-of-pocket business
     expenses that are reasonably incurred by you in furtherance of the
     Company's business in accordance with the Company's policies with respect
     thereto as in effect from time to time.

     4. Termination. The Employment Term shall end upon the earliest of the
     following to occur:

          (a) Your death.

          (b) Upon written notice to you of termination as a result of your
     Permanent Disability. "Permanent Disability" means your inability, by
     reason of any physical or mental impairment, to substantially perform your
     duties and responsibilities hereunder for two or more periods of 90 days
     each in any 360-day period, as determined by a qualified physician with no
     history of prior dealings with you or the Company, as reasonably agreed
     upon by you (or, if you are unable to make such selection, by an adult
     member of your immediate family) and the Company. Such physician's written
     determination of your Permanent Disability shall, upon delivery to the
     Company, be final and conclusive for purposes of this Agreement.

          (c) Your termination by the Company for "cause" as evidenced by, and
     effective upon, delivery by the Company to you of a Notice of Termination
     (as defined in Section 5 below). "Cause" shall mean, for purposes of this
     Agreement, (i) an act of fraud or embezzlement against the Company or an
     unauthorized disclosure of Confidential Information (as defined in Section
     8(a)(iv) hereof) of the Company, in each case which is willful and results
     in material damage to the Company, (ii) any criminal violation of the
     Securities Act of 1933 or the Securities Exchange Act of 1934, (iii) your
     conviction (or a plea of nolo contendere) of any felony, (iv) your gross
     neglect of your duties or your willful and continuing refusal to perform
     your duties, provided you have been given written notice of such neglect or
     refusal and within 30 days have failed to cure such neglect and refusal, or
     (v) your material willful misconduct with respect to the business or
     affairs of the Company.

          (d) Your termination of your employment for "good reason" by
     delivering to the Company a Notice of Termination (as defined in Section 5
     below) not less than 30

                                        5
<PAGE>
     days prior to the effective date of such termination. For purposes of this
     Agreement, "good reason" shall mean the occurrence of any of the events
     hereinafter set forth which are not cured by the Company within 30 days
     after the Company has received written notice from you specifying the
     particular events or conditions which constitute "good reason":

          (i)  a material reduction in your duties, title, responsibilities,
               authority, status, or reporting responsibilities unless you have
               previously consented in writing to such reduction (which consent
               may be given or withheld in your sole discretion);

          (ii) a material reduction in your Base Salary or the range of your
               target bonus; or;

          (iii) the Company's requiring you to be based more than 35 miles from
               the Company's current headquarters in Melville, New York or to
               any location for which the average commute from your residence
               exceeds 45 minutes; or

          (iv) change of control (as defined in Section 7 hereof).

          (e) Termination of your employment by the Company "without cause" by
     delivery by the Company to you of a Notice of Termination (as defined in
     Section 5 below) not less than 30 days prior to the effective date of such
     termination. Your termination by the Company shall be considered to be
     "without cause" if you are terminated or dismissed by the Company for
     reasons other than death, permanent disability or for "cause".

          (f) Your termination of your employment "without good reason" by
     delivery by you to the Company of a Notice of Termination (as defined in
     Section 5 below). Your termination of your employment shall be considered
     to be "without good reason" unless you resign for "good reason" (as defined
     in Section 4(d)).

     5. Notice of Termination. Any termination by the Company or by you shall be
     communicated by a written "Notice of Termination" to the other party
     hereto. A "Notice of Termination" shall mean a notice which indicates a
     termination date and the specific termination provision in this Agreement
     relied upon and which sets forth in reasonable detail the facts and
     circumstances claimed to provide a basis for termination under the
     provision so indicated.

     6. Payments Upon Termination.

          (a) Upon termination of your employment for any reason you will become
     entitled to (i) any accrued and unpaid Base Salary up to the date of
     termination, and (ii) any accrued and unpaid vacation pay up to the date of
     termination ((i) and (ii) being collectively referred to as the "Accrued
     Compensation").

          (b) Upon termination of your employment due to death or Permanent
     Disability, in addition to Accrued Compensation, you (or your estate, as
     the case may be)

                                        6
<PAGE>
     will become entitled to an amount equal to the bonus that you would have
     been entitled to receive for the fiscal year in which your termination
     occurs had you continued to be employed until the end of such fiscal year,
     multiplied by a fraction (i) the numerator of which is the number of days
     in such fiscal year through the termination date and (ii) the denominator
     or which is 365 (a "Pro-rata Bonus").

          (c) Upon a termination of your employment by the Company "without
     cause" or by you "for good reason" or upon a "Change of Control" (as
     defined in Section 7 hereof), in addition to Accrued Compensation, you will
     become entitled to (i) your Base Salary for 12 months following the date of
     termination, (ii) your Pro-rata Bonus, and (iii) continued coverage for 12
     months following termination under any health and dental program in which
     you were eligible to participate as of the time of termination of your
     employment.

          (d) You shall not be required to mitigate the amount of any payment
     provided for under this Section 6 by seeking other employment or otherwise
     and no payment shall be offset or reduced by the amount of any compensation
     or benefits provided to you in any subsequent employment. The Company's
     obligation to make the payments provided for in this Section 6 and
     otherwise perform its obligations hereunder shall not be affected by any
     circumstances, including, without limitation, set-off, counterclaim,
     recoupment, defense or other claim, right or action which the Company may
     have against you or others.

     7. Change of Control. For purposes of this Agreement, a "Change of Control"
     shall mean the approval by stockholders of the Company of (a) a merger or
     consolidation involving the Company if the stockholders of the Company,
     immediately before such merger or consolidation, do not, as a result of
     such merger or consolidation, directly or indirectly, continue to hold
     greater than 60% of the voting power in the resulting entity, or (b) an
     agreement for the sale or other disposition of all or substantially all of
     the assets of the Company.

     8. Prohibited Activities.

          (a)  Certain Acknowledgements and Agreements.

               (i) We have discussed, and you recognize and acknowledge the
          competitive and proprietary aspects of the business of the Company.

               (ii) You acknowledge that your employment by the Company creates
          a relationship of confidence and trust between the Company and you
          with respect to certain information relating to the business and
          affairs of the Company or applicable to the business of any client,
          customer, consultant, partner, external collaborator or service
          provider of the Company, which may be made known to you by the Company
          or by any client, customer, consultant, partner, external collaborator
          or service provider of the Company, or learned by you during the
          period of your affiliation with the Company.

                                        7
<PAGE>
               (iii) You further acknowledge that, while you are employed
          hereunder, the Company will furnish, disclose or make available to you
          Confidential Information (as defined in Section 8 (a) (iv) below)
          related to the business of the Company (whether or not the information
          has commercial value to the Company's business). You also acknowledge
          that such Confidential Information has been developed and will be
          developed by the Company through the expenditure by the Company of
          substantial time, effort and money and that all such Confidential
          Information could be used by you to compete with the Company. You also
          acknowledge that if you become employed or affiliated with any
          competitor of the Company, it is possible that you would disclose
          Confidential Information to such competitor and would use Confidential
          Information, knowingly or unknowingly, on behalf of such competitor.

               (iv) For purposes of this Agreement, "Confidential Information"
          means confidential and proprietary information of the Company, whether
          in written, oral, electronic or other form, including, without
          limitation, systems, processes, formulae, data, functional
          specifications, computer software, programs and displays, know-how,
          improvements, discoveries, inventions, developments, designs,
          techniques, marketing plans, strategies, forecasts, new and proposed
          products and technologies, unpublished financial statements and
          financial information, business plans, budgets, projections, licenses,
          prices, costs, training methods and materials, sales prospects, and
          customer, supplier, manufacturer, collaborator, partner, and client
          lists and any and all intellectual properties, including any
          scientific, technical or trade secrets of the Company or of any third
          party provided to you or the Company under a condition of
          confidentiality, provided that Confidential Information will not
          include information that is in the public domain other than through
          any fault or act by you.

          (b) Covenants. While you are employed hereunder and for a period of
     one year following the termination of your employment hereunder for any
     reason or for no reason, you will not, without the prior written consent of
     the Company:

               (i) Engage, directly or indirectly, for your benefit or the
          benefit of others, in any activity or employment in the performance of
          which any Confidential Information obtained during the course of your
          employment would, by necessity, need to be disclosed by you in order
          to engage in any such activity or employment. This covenant shall not
          be construed to limit in any way your obligation not to use or
          disclose Confidential Information as set forth in Section 9 below.

               (ii) Either individually or on behalf of or through any third
          party, directly or indirectly, solicit, divert or appropriate or
          attempt to solicit, divert or appropriate, any customers of the
          Company or any prospective customers with respect to which the Company
          has developed or made a sales presentation (or similar offering of
          services) for the purpose of directly competing with the Company with
          respect to the Company's "principal marketed products" (i.e., those
          products which are in the first or second detail position) or its
          development

                                        8
<PAGE>
          candidates which have material financial significance to the Company
          and which are in Phase III programs; or

               (iii) Either individually or on behalf of or through any third
          party, directly or indirectly, (A) solicit, entice or persuade or
          attempt to solicit, entice or persuade any employees of or consultants
          to the Company to leave the service of the Company for any reason, or
          (B) employ, cause to be employed, or solicit the employment of, any
          employees of or consultants to the Company while any such person is
          providing services to the Company or within six months after any such
          person has ceased providing services to the Company; or

               (iv) Either individually or on behalf of or through any third
          party, directly or indirectly, interfere with, or attempt to interfere
          with, the relations between the Company and any manufacturer or
          supplier to or customer of the Company.

          (c) Reasonableness of Restrictions. You understand that the provisions
     set forth in Section 8(b) are not meant to prevent you from earning a
     living or fostering your career. They are intended, however, to prevent
     competitors of the Company from gaining an unfair advantage from your
     knowledge of Confidential Information. You understand that, by making any
     other employer aware of the provisions set forth in this Section 8, that
     employer can take such action as to avoid your breach of this Section 8.

          (d) Survival of Acknowledgements and Agreements. Your acknowledgements
     and agreements set forth in this Section 8 will survive the termination of
     this Agreement and the termination of your employment hereunder for any
     reason or for no reason.

     9. Protected Information. All Confidential Information shall be the sole
     property of the Company and its assigns. You hereby assign to the Company
     any right you may have or acquire in such Confidential Information. You
     will at all times, both during the period while you are employed hereunder
     and after the termination of this Agreement and the termination of your
     employment hereunder for any reason or for no reason, maintain in
     confidence and will not, without the prior written consent of the Company,
     use, except as required in the course of performance of your duties for the
     Company or by court order, disclose or give to others any Confidential
     Information. In the event you are questioned by anyone not employed by the
     Company or by an employee of or a consultant to the Company not authorized
     to receive Confidential Information, in regard to any Confidential
     Information, or concerning any fact or circumstance relating thereto, you
     will promptly notify the Company. Upon the termination of your employment
     hereunder for any reason or for no reason, or if the Company otherwise
     requests, you will return to the Company all tangible Confidential
     Information and copies thereof (regardless how such Confidential
     Information or copies are maintained). The terms of this Section 9 are in
     addition to, and not in lieu of, any statutory or other contractual or
     legal obligation that you may have relating to the protection of the
     Company's Confidential Information. The terms of this Section 9 will
     survive indefinitely any termination of this Agreement and/or any
     termination of your employment hereunder for any reason or for no reason.

                                        9
<PAGE>
     10. Ownership of Ideas, Copyrights and Patents.

          (a) Property of the Company. All ideas, discoveries, creations,
     manuscripts and properties, innovations, improvements, know-how,
     inventions, designs, developments, apparatus, techniques, methods,
     biological processes, cell lines, laboratory notebooks and formulae
     (collectively, the "Inventions") which may be used in the current or
     planned business of the Company or which in any way relates to such
     business, whether patentable, copyrightable or not, which you may conceive,
     reduce to practice or develop while you are employed hereunder (and, if
     based on or related to any Confidential Information, within two years after
     termination of such employment for any reason or for no reason), alone or
     in conjunction with another or others, whether during or out of regular
     business hours, whether or not on the Company's premises or with the use of
     its equipment, and whether at the request or upon the suggestion of the
     Company or otherwise, will be the sole and exclusive property of the
     Company, and that you will not publish any of the Inventions without the
     prior written consent of the Company. Without limiting the foregoing, you
     also acknowledge that all original works of authorship which are made by
     you (solely or jointly with others) within the scope of your employment or
     which relate to the business of the Company and which are protectable by
     copyright are "works made for hire" pursuant to the United States Copyright
     Act (17 U.S.C. Section 101). You will promptly disclose to the Company all
     of the foregoing and you hereby assign to the Company all of your right,
     title and interest in and to all of the foregoing. You further represent
     that, to the best of your knowledge and belief, none of the Inventions will
     violate or infringe upon any right, patent, copyright, trademark or right
     of privacy, or constitute libel or slander against or violate any other
     rights of any person, firm or corporation, and that you will use your best
     efforts to prevent any such violation.

          (b) Cooperation. At any time during your employment hereunder or after
     the termination of your employment hereunder for any reason or for no
     reason, you will cooperate fully with the Company and its attorneys and
     agents in the preparation and filing of all papers and other documents as
     may be required to perfect the Company's rights in and to any of such
     Inventions, including, without limitation, joining in any proceeding to
     obtain letters patent, copyrights, trademarks or other legal rights with
     respect to any such Inventions in the United States and in any and all
     other countries, provided that the Company will bear the expense of such
     proceedings, and that any patent or other legal right so issued to you
     personally will be assigned by you to the Company without charge by you.

          (c) Licensing and Use of Inventions. With respect to any Inventions,
     and work of any similar nature (from any source), whenever created, which
     you have not prepared or originated in the performance of your employment,
     but which you provide to the Company or incorporate in any Company product
     or system, you hereby grant to the Company a royalty-free, fully paid-up,
     non-exclusive, perpetual and irrevocable license throughout the world to
     use, modify, create derivative works from, disclose, publish, translate,
     reproduce, deliver, perform, dispose of, and to authorize others so to do,
     all such Inventions. You will not include in any Inventions you deliver to
     the Company or

                                       10
<PAGE>
     use on its behalf, without the prior written approval of the Company, any
     material which is or will be patented, copyrighted or trademarked by you or
     others unless you provide the Company with the written permission of the
     holder of any patent, copyright or trademark owner for the Company to use
     such material in a manner consistent with then-current Company policy.

          (d) Prior Inventions. Listed on Exhibit 10(d) to this Agreement are
     any and all Inventions in which you claim or intend to claim any right,
     title and interest (collectively, "Prior Inventions"), including, without
     limitation, patent, copyright and trademark interests, which to the best of
     your knowledge will be or may be delivered to the Company in the course of
     your employment, or incorporated into any Company product or system. You
     acknowledge that your obligation to disclose such information is ongoing
     while you are employed hereunder.

     11. Records. Upon termination of your employment hereunder for any reason
     or for no reason and at any other time requested by the Company, you will
     deliver to the Company any property of the Company which may be in your
     possession, including products, materials, memoranda, notes, records,
     reports, or other documents or photocopies of the same.

     12. Representations. You hereby represent and warrant to the Company that
     you understand this Agreement, that you enter into this Agreement
     voluntarily and that your employment under this Agreement will not conflict
     with any legal duty owed by you to any other party, or with any agreement
     to which you are a party or by which you are bound, including, without
     limitation, any non-competition or non-solicitation provision contained in
     any such agreement.

     13. General.

          (a) Notices. All notices, requests, consents and other communications
     hereunder which are required to be provided, or which the sender elects to
     provide, in writing, will be addressed to the receiving party's address set
     forth above or to such other address as a party may designate by notice
     hereunder, and will be either (i) delivered by hand, (ii) sent by overnight
     courier, or (iii) sent by registered or certified mail, return receipt
     requested, postage prepaid. All notices, requests, consents and other
     communications hereunder will be deemed to have been given either (i) if by
     hand, at the time of the delivery thereof to the receiving party at the
     address of such party set forth above, (ii) if sent by overnight courier,
     on the next business day following the day such notice is delivered to the
     courier service, or (iii) if sent by registered or certified mail, on the
     fifth business day following the day such mailing is made.

          (b) Entire Agreement. This Agreement, and the other agreements
     specifically referred to herein, embodies the entire agreement and
     understanding between the parties hereto with respect to the subject matter
     hereof and supersedes all prior oral or written agreements and
     understandings relating to the subject matter hereof. No statement,
     representation, warranty, covenant or agreement of any kind not expressly
     set forth in this

                                       11
<PAGE>
     Agreement will affect, or be used to interpret, change or restrict, the
     express terms and provisions of this Agreement.

          (c) Modifications and Amendments. The terms and provisions of this
     Agreement may be modified or amended only by written agreement executed by
     the parties hereto.

          (d) Waivers and Consents. The terms and provisions of this Agreement
     may be waived, or consent for the departure therefrom granted, only by
     written document executed by the party entitled to the benefits of such
     terms or provisions. No such waiver or consent will be deemed to be or will
     constitute a waiver or consent with respect to any other terms or
     provisions of this Agreement, whether or not similar. Each such waiver or
     consent will be effective only in the specific instance and for the purpose
     for which it was given, and will not constitute a continuing waiver or
     consent.

          (e) Assignment. The Company may assign its rights and obligations
     hereunder to any person or entity that succeeds to all or substantially all
     of the Company's business or that aspect of the Company's business in which
     you are principally involved or to any Company Affiliate; provided, that
     the Company shall remain responsible for any payments and obligations to
     you to the extent any assignee fails to fulfill such payments and
     obligations. You may not assign your rights and obligations under this
     Agreement without the prior written consent of the Company and any such
     attempted assignment by you without the prior written consent of the
     Company will be void.

          (f) Benefit. All statements, representations, warranties, covenants
     and agreements in this Agreement will be binding on the parties hereto and
     will inure to the benefit of the respective successors and permitted
     assigns of each party hereto. Nothing in this Agreement will be construed
     to create any rights or obligations except between the Company and you,
     except for your obligations to the Company as set forth herein, and no
     person or entity (except for a Company Affiliate as set forth herein) will
     be regarded as a third-party beneficiary of this Agreement.

          (g) Governing Law. This Agreement and the rights and obligations of
     the parties hereunder will be construed in accordance with and governed by
     the laws of the State of New York, without giving effect to the conflict of
     law principles thereof.

          (h) Jurisdiction, Venue and Service of Process. Any legal action or
     proceeding with respect to this Agreement that is not subject to
     arbitration pursuant to Section 14 (i) below will be brought in the courts
     of Suffolk County, New York. By execution and delivery of this Agreement,
     each of the parties hereto accepts for itself and in respect of its
     property, generally and unconditionally, the exclusive jurisdiction of the
     aforesaid courts.

          (i) Arbitration. Any controversy, dispute or claim arising out of or
     in connection with this Agreement, other than a controversy, dispute or
     claim arising under Section 8, 9 or 10 hereof, will be settled by final and
     binding arbitration to be conducted in New York, New York pursuant to the
     national rules for the resolution of employment disputes of the American
     Arbitration Association then in effect. The decision or award in

                                       12
<PAGE>
     any such arbitration will be final and binding upon the parties and
     judgment upon such decision or award may be entered in any court of
     competent jurisdiction or application may be made to any such court for
     judicial acceptance of such decision or award and an order of enforcement.
     In the event that any procedural matter is not covered by the aforesaid
     rules, the procedural law of New York will govern. Any disagreement as to
     whether a particular dispute is arbitrable under this Agreement shall
     itself be subject to arbitration in accordance with the procedures set
     forth herein. The fees of the arbitrators shall be paid by the Company.

          (j) WAIVER OF JURY TRIAL. ANY ACTION, DEMAND, CLAIM OR COUNTERCLAIM
     ARISING UNDER OR RELATING TO THIS AGREEMENT THAT IS NOT SUBJECT TO
     ARBITRATION PURSUANT TO SECTION 14(i) ABOVE WILL BE RESOLVED BY A JUDGE
     ALONE AND EACH OF YOU AND THE COMPANY WAIVE ANY RIGHT TO A JURY TRIAL
     THEREOF.

          (k) Severability. The parties intend this Agreement to be enforced as
     written. However, (i) if any portion or provision of this Agreement is to
     any extent declared illegal or unenforceable by a duly authorized court
     having jurisdiction, then the remainder of this Agreement, or the
     application of such portion or provision in circumstances other than those
     as to which it is so declared illegal or unenforceable, will not be
     affected thereby, and each portion and provision of this Agreement will be
     valid and enforceable to the fullest extent permitted by law and (ii) if
     any provision, or part thereof, is held to be unenforceable because of the
     duration of such provision, the geographic area covered thereby, or other
     aspect or scope of such provision, the court making such determination will
     have the power to reduce the duration, geographic area of such provision,
     or other aspect or scope of such provision, and/or to delete specific words
     and phrases ("blue-penciling"), and in its reduced or blue-penciled form,
     such provision will then be enforceable and will be enforced.

          (l) Injunctive Relief. You hereby expressly acknowledge that any
     breach or threatened breach of any of the terms and/or conditions set forth
     in Section 8, 9 or 10 of this Agreement will result in substantial,
     continuing and irreparable injury to the Company. Therefore, in addition to
     any other remedy that may be available to the Company, the Company will be
     entitled to injunctive or other equitable relief by a court of appropriate
     jurisdiction in the event of any breach or threatened breach of the terms
     of Section 8, 9 or 10 of this Agreement. The period during which the
     covenants contained in Section 8 will apply will be extended by any periods
     during which you are found by a court to have been in violation of such
     covenants.

          (m) No Waiver of Rights, Powers and Remedies. No failure or delay by a
     party hereto in exercising any right, power or remedy under this Agreement,
     and no course of dealing between the parties hereto, will operate as a
     waiver of any such right, power or remedy of the party. No single or
     partial exercise of any right, power or remedy under this Agreement by a
     party hereto, nor any abandonment or discontinuance of steps to enforce any
     such right, power or remedy, will preclude such party from any other or
     further exercise thereof or the exercise of any other right, power or
     remedy hereunder. The election of any remedy by a party hereto will not
     constitute a waiver of the right of such party to pursue other available
     remedies. No notice to or demand on a party not expressly required under

                                       13
<PAGE>
     this Agreement will entitle the party receiving such notice or demand to
     any other or further notice or demand in similar or other circumstances or
     constitute a waiver of the rights of the party giving such notice or demand
     to any other or further action in any circumstances without such notice or
     demand.

          (n) Counterparts. This Agreement may be executed in two or more
     counterparts, and by different parties hereto on separate counterparts,
     each of which will be deemed an original, but all of which together will
     constitute one and the same instrument.

          (o) Opportunity to Review. You hereby acknowledge that you have had
     adequate opportunity to review these terms and conditions and to reflect
     upon and consider the terms and conditions of this Agreement, and that you
     have had the opportunity to consult with counsel of your own choosing
     regarding such terms. You further acknowledge that you fully understand the
     terms of this Agreement and have voluntarily executed this Agreement.

          (p) Survival of the Company's Obligations. Notwithstanding the
     termination of this agreement pursuant to Section 4, the Company's
     obligation to make payments and provide benefits to you as set forth in
     Section 3 (g) (iv) and Section 6 will remain in effect.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       14
<PAGE>
     If the foregoing accurately sets forth our agreement, please so indicate by
signing and returning to us the enclosed copy of this Agreement.

                                        Very truly yours,

                                        OSI Pharmaceuticals, Inc.

                                        By: /s/
                                            ------------------------------------
                                        Name: Colin Goddard, Ph.D
                                        Title: Chief Executive Officer

Accepted and Approved:

/s/                                     April 21, 2005
-------------------------------------   Date
Michael Atieh

                                       15
<PAGE>
                                  EXHIBIT 10(d)

                                PRIOR INVENTIONS

                                       16<PAGE>

                                                                     EXHIBIT 4.1

                              DATED           2005

                         OSI PHARMACEUTICALS, INC. (1)
                                      AND
                           'FIRST-NAME' 'SURNAME' (2)

        ---------------------------------------------------------------

                     DEED OF SHARE EXCHANGE RELATING TO THE
                          SHARES OF PROSIDION LIMITED
        ---------------------------------------------------------------
<PAGE>

                               TABLE OF CONTENTS

<Table>
<S>   <C>                                                           <C>
      Definitions and Interpretation..............................
1                                                                     1
      Exchange of Shares..........................................
2                                                                     2
      Representations.............................................
3                                                                     2
      Completion..................................................
4                                                                     4
      Further Assurance...........................................
5                                                                     5
      Invalidity..................................................
6                                                                     5
      Non-Assignment..............................................
7                                                                     5
      Notices.....................................................
8                                                                     5
      Third Party Rights..........................................
9                                                                     6
      Variation...................................................
10                                                                    6
      Waiver......................................................
11                                                                    6
      Entire Agreement............................................
12                                                                    6
      Counterparts................................................
13                                                                    6
      Governing Law...............................................
14                                                                    6
</Table>
<PAGE>

                             DEED OF SHARE EXCHANGE

THIS DEED is made the   day of           2005

BETWEEN:

     (1) OSI PHARMACEUTICALS, INC., a company incorporated under the laws of the
state of Delaware, USA and having its registered office at 58 South Service
Road, Melville, New York, 11747, USA (the "PARENT COMPANY"); and

     (2) 'FIRST-NAME' 'SURNAME' of 'Address-1', 'Address-2', 'Address-3',
'Address-4' 'Address-5' (the "MEMBER"),
(each a "PARTY" and collectively the "PARTIES").

RECITALS:

     (A) WHEREAS Prosidion Limited was incorporated under the laws of England
and Wales on 25 November 2002 (registered number 4600121) and has an authorised
share capital of 2,000 pound divided into 14,000,000 Preferred Ordinary Shares
of 0.0001 Pound each ("PREFERRED ORDINARY SHARES"); 4,000,000 A Ordinary Shares
of 0.0001 Pound each ("A ORDINARY SHARES"); and 2,000,000 B Ordinary Shares of
0.0001 ("B ORDINARY SHARES") each.

     (B) WHEREAS 'FounderIIBIIShares' B Ordinary Shares (the "SHARES") have been
issued and allotted to the Member.

     (C) WHEREAS the Member is the legal and beneficial owner of the Shares.

     (D) WHEREAS the Parent Company has proposed to acquire all of the Shares
from the Member in exchange for common stock, par value $0.01 per share of the
Parent Company ("PARENT COMPANY STOCK").

     (E) WHEREAS the Member and the Parent Company have agreed to the exchange
of the Shares in return for the issue of Parent Company Stock on the terms and
conditions set out in this Deed.

     (F) WHEREAS, the offer and issuance of the Consideration Stock, as defined
below, by the Parent Company is made pursuant to Regulation S under the
Securities Act of 1933, as amended (the "SECURITIES ACT").

NOW IT IS AGREED AS FOLLOWS:

1  DEFINITIONS AND INTERPRETATION

     1.1 In this Deed, subject to any express contrary indication:

          (a) words importing the singular shall include the plural and vice
     versa;

          (b) any reference to this Deed or any other agreement or document
     shall be construed as a reference to that agreement or document as it may
     have been, or may from time to time be, amended, varied, novated, replaced
     or supplemented;

          (c) any reference to a statute or enactment shall be construed as a
     reference to such statute as it may have been, or may from time to time be,
     amended or re-enacted and any subordinate legislation made or thing done,
     or may from time to time be done, under the statute or enactment provided
     that, as between the parties, no such amendment or modification shall apply
     for the purposes of this Deed to the extent that it would impose any new or
     extended obligation, liability or restriction on, or otherwise adversely
     affect the rights of, any party; and

          (d) any reference to any English legal term for any action, remedy,
     method of judicial proceeding, legal document, legal status, court,
     official, or any legal concept or thing shall in respect of any
     jurisdiction (other than England) be deemed to include what most nearly
     approximates in that jurisdiction to the English legal term.

                                        1
<PAGE>

     1.2 All headings in this Deed are for ease of reference only and shall not
affect the interpretation of this Deed.

     1.3 Capitalised terms used in the Recitals and this Deed shall, unless the
context otherwise requires, have the meaning set out in the Articles of
Association of the Company.

2  EXCHANGE OF SHARES

     2.1 EXCHANGE RATIO

     For the purposes of this Deed the Parent Company and the Member agree that
the Shares shall be exchanged for Parent Company Stock on the basis of the
following exchange ratio (the "EXCHANGE RATIO"):

             For each Share: 0.29685 shares of Parent Company Stock

     2.2 NO FRACTIONAL SHARES

     No certificates representing fractional shares of the Parent Company Stock
shall be issued, and such fractional share interests will not entitle the Member
to vote or to any other rights of a stockholder of the Parent Company. With
respect to any fractional share interest to which the Member is entitled, the
Member shall be paid an amount in cash equal to the product obtained by
multiplying (i) such fractional share interest to which the Member would
otherwise be entitled by (ii) $53.90.

     2.3 EXCHANGE OF SHARES

     At Completion, in consideration for the Parent Company issuing to the
Member the 'OSIPIIShares' shares of Parent Company Stock (the "Consideration
Stock"), the Member as legal and beneficial owner shall transfer its Shares to
the Parent Company with full title guarantee free from any lien, claim, charge,
security interest, mortgage, pledge, easement, conditional sale or other title
retention agreement, defect in title, rights of third parties, restrictive
covenant or other restrictions of any kind (each an "ENCUMBRANCE").

3  REPRESENTATIONS AND COVENANTS

     3.1 The Member represents and warrants to the Parent Company at the date
hereof that:

          (a) he/she is the legal and beneficial owner of the Shares;

          (b) there is no Encumbrance on, over or affecting any of the Shares;

          (c) no agreement to create an Encumbrance has been entered into and no
     claim has been made by any person (natural or otherwise) that it is
     entitled to any such Encumbrance; and

          (d) he/she has full power and authority to enter into and exercise its
     rights and perform its obligations under this Deed and all other documents
     to be executed by him/her at Completion;

          (e) his/her obligations under this Deed are valid and binding subject
     to applicable law.

     3.2 In respect of U.S. securities laws, the Member represents and warrants
to the Parent Company at the date hereof that:

          (a) the Member is not a "U.S." person as defined in Regulation S under
     the Securities Act, (i.e., the Member is not resident in the United
     States);

          (b) the Member is not acquiring the Consideration Stock for the
     account or benefit of any other person;

          (c) the Member received a copy of this Deed from the Parent Company
     while the Member was outside of the United States and, when signed, will
     have signed this Deed and delivered a signed copy of this Deed to the
     Parent Company while the Member was outside of the United States;

                                        2
<PAGE>

          (d) the Member (i) has been granted the opportunity to ask questions
     of, and receive answers from, representatives of the Parent Company
     concerning the terms and conditions of the exchange and (ii) has requested,
     received, reviewed and considered all information that he/she has deemed
     relevant in making an informed decision to acquire the Consideration Stock;

          (e) the Member has been advised of and understands the risks of an
     investment in the Consideration Stock;

          (f) the Member acknowledges that the acquisition of the Consideration
     Stock has not been registered under the Securities Act or registered or
     qualified under any U.S. state securities law in reliance on specific
     exemptions therefrom, which exemptions depend upon, among other things, the
     Member's representations and covenants as expressed in this Deed;

          (g) the Member has been informed and understands that the
     Consideration Stock may not be sold except (i) pursuant to a registration
     statement, (ii) pursuant to an exemption from registration, or (iii) in
     compliance with Rule 144 of the Securities Act (and is therefore subject to
     the holding requirements of Rule 144 of the Securities Act);

          (h) the Member has not undertaken any activities in the United States
     for the purpose of conditioning the market in the United States for the
     resale of the Consideration Stock by the Member or any other person
     acquiring securities of the Parent Company; and

          (i) the Member has no direct or indirect affiliation or association
     with any member of the National Association of Securities Dealers, Inc. in
     the United States (the "NASD").

     3.3 In respect of U.S. securities laws, the Member covenants with the
Parent Company that:

          (a) The Member will not, directly or indirectly, offer, sell, pledge,
     transfer or otherwise dispose of or solicit any offers to buy any of the
     Consideration Stock except in compliance with the Securities Act and
     applicable state securities laws. In furtherance thereof, the Member will
     not make any disposition of the Consideration Stock except (i) pursuant to
     a registration statement under the Securities Act covering such proposed
     disposition, (ii) upon prior notice to the Parent Company and, if
     reasonably requested by the Parent Company, delivery to the Parent Company
     of an opinion of counsel, reasonably satisfactory to the Parent Company,
     that such disposition will not require registration under the Securities
     Act, or (iii) in compliance with Rule 144 under the Securities Act.

          (b) The Member acknowledges and agrees that no action has been or is
     intended to be taken in any jurisdiction outside the United States by the
     Parent Company that would permit an offering of the Consideration Stock or
     possession or distribution of offering materials in connection with the
     issuance of the Consideration Stock, in any jurisdiction outside the United
     States where legal action by the Parent Company for that purpose is
     required. The Member outside the United States will comply with all
     applicable laws and regulations in each foreign jurisdiction in which
     he/she purchases, offers, sells or delivers Consideration Stock or has in
     its possession or distributes any offering material, in all cases at
     his/her own expense.

          (c) The Member has been advised that he/she may not engage in any
     hedging transactions with regard to the Consideration Stock unless
     conducted in compliance with the Securities Act. However, the Member agrees
     that pursuant to the Parent Company's "Statement of Company Policy on
     Securities Trades by Company Personnel and Directors," he/she will not
     engage in any hedging transactions in the Consideration Stock or other
     securities of the Parent Company.

          (d) The Member understands and acknowledges that certificates
     evidencing the Consideration Stock shall bear one or all of the following
     legends or a similar legend:

             "The shares represented by this certificate have not been
        registered under the Securities Act of 1933, as amended (the "Act"), and
        may not be transferred without (i) an opinion of counsel satisfactory to
        the corporation that such transfer may lawfully be made without
        registration under such Act or qualification under applicable state
        securities laws; or (ii) such registration or

                                        3
<PAGE>

        qualification. Hedging transactions involving the shares represented by
        this certificate may not be conducted unless in compliance with the
        Act."

             If required by the authorities of any state in the United States in
        connection with the issuance of sale of the Consideration Stock, the
        legend required by such state authority.

          Any purchaser of the Consideration Stock pursuant to an effective
     registration statement under the Securities Act will be entitled to receive
     a certificate bearing no restrictive legend.

4  COMPLETION

     4.1 Completion shall take place at the offices of Prosidion Limited,
Watlington Road, Oxford, OX4 6LT on April 14, 2005 (the "COMPLETION"). At
Completion, the Member shall deliver to the Parent Company:

          (a) duly executed transfers of his/her Shares in favour of the Parent
     Company together with all share certificates relating to the Shares or, in
     the absence of which, an indemnity letter relating to loss of such share
     certificate; and

          (b) any other documents which may be required to vest in the Parent
     Company the full legal and beneficial ownership of the Shares and enable
     the Parent Company to procure them to be registered in its name or as it
     may direct.

     4.2 At Completion the Member IRREVOCABLY AND UNCONDITIONALLY APPOINTS the
Parent Company and each of Colin Goddard of 30 Allenby Drive, Fort Solonga, NY
11768, USA, Bob Van Nostrand of 15 Mariners Circle, West Islip, NY 11797, USA
and Barbara Wood of 200 West 90th Street, Apartment 12F, New York, NY 10024,
USA, each acting severally (each an "ATTORNEY") to be the true and lawful
Attorney of the Member, with full power to appoint substitutes, pending
registration of the Parent Company as the legal owner of the Shares and in
his/her name or otherwise on his/her behalf as the Attorney sees fit to execute
notices, instruments of proxy or other documents which may fall to be executed
or signed by the Member and exercise and perform any of the acts and things to
be done and performed by the Member in connection with the legal and beneficial
ownership of all or any of the Shares held by the Member as if the Attorney were
the legal and beneficial owner of such Shares and in particular but without
limitation the Attorney is appointed to:

          (a) attend any General Meeting (Annual and/or Extraordinary) of the
     Company and to represent the Member and vote on the Member's behalf and in
     his/her name;

          (b) exercise in the Member's name and on his/her behalf, all rights
     and privileges attached to his/her Shares including but not limited to the
     right to requisition the convening of an Extraordinary General Meeting;

          (c) to receive, in the Member's name and on his/her behalf, any notice
     or document which the Member is entitled to receive solely by virtue of
     being the registered holder of the Shares including the right to receive
     all benefits and entitlements which attach to the Shares from the date of
     Completion. For the avoidance of doubt this paragraph (c) does not cover
     Consideration Stock to be issued to the Member pursuant to his/her
     agreement with the Parent Company relating to the exchange of the Shares;
     and

          (d) execute and do (or procure the execution and giving of) such
     documents, acts and things as in the opinion of the Attorney is desirable
     and in such manner as the Attorney thinks fit as if the Attorney were the
     absolute legal and beneficial owner thereof.

     4.3 The power of attorney granted in Clause 4.2 shall expire on the date on
which the Parent Company is registered as the holder of the Shares in the
register of members of the Company.

     4.4 The Member undertakes to ratify everything which the Attorney shall do
or purport to do in good faith by virtue of the powers granted by the power of
attorney granted in Clause 4.2.

                                        4
<PAGE>

     4.5 Within seven days of the Parent Company receiving the documents
referred to in Clause 4.1 from the Member, it shall issue the Consideration
Stock to the Member and shall procure that the Member is registered as a
stockholder in the Parent Company in respect of his/her Consideration Stock.

          (a) If the Member fails or refuses to accept delivery of Consideration
     Stock then it shall be set aside by the Parent Company. Such setting aside
     shall be deemed, for all purposes of this Clause 4, to be a payment to the
     Member and all the Member's rights as a member of the Company shall cease
     as from the Completion Date and the Parent Company shall be discharged, on
     such setting aside, from all obligations in respect of the same. The Parent
     Company shall not be responsible for the safe custody of the Consideration
     Stock so set aside (which shall be held by the Parent Company for a maximum
     period of 12 years, after which period the Parent Company shall be entitled
     to cancel the Consideration Stock in full).

          (b) A receipt by the Member of stock certificates relating to his/her
     Consideration Stock due on exchange of his/her Shares shall constitute an
     absolute discharge to the Parent Company for all its obligations relating
     thereto.

     4.6 The Parent Company undertakes to file with U.S. Securities and Exchange
Commission a registration statement with respect to the resale of the Parent
Company Stock and have such registration statement declared effective according
to the terms set forth in Annex A to this Deed.

5  FURTHER ASSURANCE

     Each Member shall, at the expense of the Parent Company, do or procure to
be done all such further acts and things and execute or procure the execution of
all such other documents as the Parent Company may from time to time reasonably
require for the purpose of giving to the Parent Company the full benefit of all
the provisions of this Deed.

6  INVALIDITY

     If any provision of this Deed is held to be invalid or unenforceable, then
such provision shall (so far as it is invalid or unenforceable) be given no
effect and shall be deemed not to be included in this Deed but without
invalidating any of the remaining provisions of this Deed. The parties shall
then use all reasonable endeavours to replace the invalid or unenforceable
provision by a valid provision the effect of which is as close as possible to
the intended effect of the invalid or unenforceable provision.

7  NON-ASSIGNMENT

     No party shall, without the consent of the others, be entitled to assign
the benefit or burden of this Deed in whole or in part with the exception of the
assignment rights set forth in Annex A to this Deed.

8  NOTICES

     8.1 Any notice to be given under this Deed shall be in writing and shall be
delivered personally or sent by pre-paid international courier to the addressee
at the address set out on the face of this Deed or such other address as may be
notified from time to time. A notice so addressed shall be deemed to have been
received:

          (a) if personally delivered, at the time of delivery; and

          (b) if sent by international courier, two days after the date of
     delivery of the notice to the international courier by the sender.

     8.2 For the avoidance of doubt, notice given under this Deed shall not be
validly served if sent by electronic mail.

                                        5
<PAGE>

9  THIRD PARTY RIGHTS

     The parties do not intend that any term of this Deed shall be enforceable
pursuant to the Contracts (Rights of Third Parties) Act 1999 by any person who
is not a party to this Deed.

10  VARIATION

     No variation of any of the terms of this Deed (or of any other documents
referred to herein) shall be valid unless it is in writing and signed by or on
behalf of each of the parties hereto. The expression "variation" shall include
any variation, supplement, deletion or replacement however effected.

11  WAIVER

     11.1 Any delay by the parties in exercising, or failure to exercise, any
right or remedy under this Deed shall not constitute a waiver of the right or
remedy or a waiver of any other rights or remedies and no single or partial
exercise of any rights or remedy under this Deed or otherwise shall prevent any
further exercise of the right or remedy or the exercise of any other right or
remedy.

     11.2 The rights and remedies of the parties under this Deed are cumulative
and not exclusive of any rights or remedies provided by law.

12  ENTIRE AGREEMENT

     This Deed, together with documents described in or expressed to be entered
into in connection with this Deed, constitutes the entire agreement between the
parties with respect to all matters referred to herein and supersede all prior
written or oral discussions, representations, negotiations and agreements among
them regarding such subject matter. Each party confirms that the terms of this
Deed are fair and reasonable.

13  COUNTERPARTS

     This Deed may be executed in as many counterparts (including facsimile
counterparts) as may be required. It shall not be necessary that the signatures
of, or on behalf of, each party, or that the signatures of all persons required
to bind any party, appear on each counterpart; but it shall be sufficient that
the signature of, or on behalf of, each party, or that the signatures of the
persons required to bind any party, appear on one or more of the counterparts.
All counterparts shall collectively constitute a single Deed. It shall not be
necessary in making proof of this Deed to produce or account for more than a
number of counterparts containing the respective signatures of, or on behalf of,
all of the parties hereto.

14  GOVERNING LAW

     14.1 This Deed shall be governed by and construed in accordance with the
laws of England and Wales.

     14.2 In relation to any legal action or proceedings arising out of or in
connection with this Deed ("PROCEEDINGS"), each of the parties irrevocably
submits to the non-exclusive jurisdiction of the English courts and waives any
objection to Proceedings in such courts on the grounds of venue or on the
grounds that Proceedings have been brought in an inappropriate forum.

                                        6
<PAGE>

     IN WITNESS WHEREOF the parties hereto have duly executed this agreement as
a deed with the intent that it is delivered as such on the day and year first
above written.

<Table>
<S>                                       <C>
EXECUTED AS A DEED                        )
BY                                        )
OSI PHARMACEUTICALS, INC.                 )
ACTING BY A DULY AUTHORISED               )
REPRESENTATIVE AND IN ACCORDANCE          )
WITH THE LAWS OF THE JURISDICTION OF      )
ITS INCORPORATION AND ARTICLES OF         )
ASSOCIATION/BY-LAWS                       )
                                          )
</Table>

                                          --------------------------------------

EXECUTED AS A DEED BY 'FIRST -- NAME' 'SURNAME'

SIGNED:
--------------------------------------

BY:
--------------------------------------

IN THE PRESENCE OF:

Witness's Signature:
----------------------------------------------------------------------------

Witness's Name:
--------------------------------------------------------------------------------

Witness's Address:
------------------------------------------------------------------------------

                                        7
<PAGE>

                                   ANNEX "A"

                  TERMS AND CONDITIONS FOR RESALE REGISTRATION

1  DEFINITIONS.

     In addition to those terms defined in the agreement, for the purposes of
this Annex A, the following terms shall have the meanings set forth here:

          1.1 "Affiliate" shall mean, with respect to any Person, any other
     Person which directly or indirectly controls, is controlled by, or is under
     common control with, such Person.

          1.2 "Closing Date" shall mean the date of Completion.

          1.3 "Common Stock" shall mean the Parent Company Stock as defined in
     Recital D of the Deed.

          1.4 "Company" shall mean the Parent Company as defined in the preamble
     of the Deed.

          1.5 "Exchange Act" shall mean the Securities Exchange Act of 1934, as
     amended, and the rules and regulations promulgated thereunder.

          1.6 "Investor" shall mean the Member as defined in the preamble of the
     Deed.

          1.7 "Nasdaq National Market" shall mean The Nasdaq Stock Market, Inc.
     National Market.

          1.8 "Person" shall mean an individual, corporation, partnership,
     trust, business trust, association, joint stock company, joint venture,
     pool, syndicate, sole proprietorship, unincorporated organization,
     governmental authority or any other form of entity not specifically listed
     herein.

          1.9 "Registration Statement" shall mean a registration statement filed
     pursuant to Section 2.1(a) of this Annex A.

          1.10 "SEC" shall mean the United States Securities and Exchange
     Commission.

          1.11 "Shares" shall mean the Consideration Stock as defined in Clause
     2.1 of the Deed.

          1.12 "Suspension" shall have the meaning set forth in Section 2.2(c)
     of this Annex A.

          1.13 "Suspension Notice" shall have the meaning set forth in Section
     2.2(c) of this Annex A.

2  REGISTRATION OF THE SHARES; COMPLIANCE WITH THE SECURITIES ACT.

     2.1 Registration Procedures and Expenses. The Company shall:

          (a) subject to prompt receipt of necessary information from the
     Investor after prompt request from the Company to the Investor to provide
     such information, use commercially reasonable efforts to prepare and file
     with the SEC, as soon as practicable after the Closing Date of the
     transactions contemplated in the Deed, a shelf registration statement (the
     "Registration Statement") to enable the resale of the Shares by the
     Investor from time to time on a delayed or continuous basis pursuant to
     Rule 415 of the Securities Act through the automated quotation system of
     the Nasdaq National Market or such other market as may be the principal
     market on which the Company's Common Stock is sold, or any other manner
     reasonably requested by the Investor, including privately-negotiated
     transactions;

          (b) use commercially reasonable efforts, subject to receipt of
     necessary information from the Investor after prompt request from the
     Company to the Investor to provide such information, to cause the
     Registration Statement to become effective as soon as practicable after the
     Registration Statement is filed by the Company;

          (c) use commercially reasonable efforts to prepare and file with the
     SEC such amendments and supplements to the Registration Statement and the
     prospectus used in connection therewith as may be

                                        8
<PAGE>

     necessary to keep the Registration Statement current and effective until
     the later of (i) two years after the Closing Date or (ii) the date on which
     all of the Shares may be sold pursuant to Rule 144 of the Securities Act
     without regard to any volume limitations;

          (d) furnish to the Investor such number of copies of the Registration
     Statement, prospectuses and preliminary prospectuses in conformity with the
     requirements of the Securities Act and such other documents as the Investor
     may reasonably request, in order to facilitate the public sale or other
     disposition of all or any of the Shares by the Investor; provided, however,
     that the obligation of the Company to deliver copies of prospectuses or
     preliminary prospectuses to the Investor shall be subject to the receipt by
     the Company of reasonable assurances from the Investor that the Investor
     will comply with the applicable provisions of the Securities Act and of
     such other securities or blue sky laws as may be applicable in connection
     with any use of such prospectuses or preliminary prospectuses;

          (e) take all reasonable actions necessary to ensure that the Shares
     are listed and available for quotation on The Nasdaq National Market;

          (f) file documents required of the Company for normal blue sky
     clearance in states specified in writing by the Investor; provided,
     however, that the Company shall not be required to qualify to do business
     or consent to service of process in any jurisdiction in which it is not now
     so qualified or has not so consented;

          (g) bear all expenses in connection with the procedures in paragraph
     (a) through (f) of this Section 2.1 and the registration of the Shares
     pursuant to the Registration Statement; and

          (h) advise the Investor promptly after it shall receive notice or
     obtain knowledge of the issuance of any stop order by the SEC delaying or
     suspending the effectiveness of the Registration Statement or of the
     initiation or threat of any proceeding for that purpose; and it will
     promptly use commercially reasonable efforts to prevent the issuance of any
     stop order or to obtain its withdrawal at the earliest possible moment if
     such stop order should be issued.

     The Company understands that the Investor disclaims being an underwriter,
but any determination by the SEC that the Investor is an underwriter shall not
relieve the Company of any obligations it has hereunder.

     2.2 Transfer of Shares After Registration; Suspension.

          (a) The Investor hereby agrees that it will not effect any disposition
     of the Shares that would constitute a sale within the meaning of the
     Securities Act except as contemplated in the Registration Statement
     referred to in Section 2.1 and as described below or as otherwise permitted
     by law, and that it will promptly notify the Company of any changes in the
     information set forth in the Registration Statement regarding the Investor
     or its plan of distribution.

          (b) Except in the event that paragraph (c) below applies, the Company
     shall (i) if deemed necessary by the Company, prepare and file from time to
     time with the SEC a post-effective amendment to the Registration Statement
     or a supplement to the related prospectus or a supplement or amendment to
     any document incorporated therein by reference or file any other required
     document so that such Registration Statement will not contain an untrue
     statement of a material fact or omit to state a material fact required to
     be stated therein or necessary to make the statements therein not
     misleading, and so that, as thereafter delivered to purchasers of the
     Shares being sold thereunder, such prospectus will not contain an untrue
     statement of a material fact or omit to state a material fact required to
     be stated therein or necessary to make the statements therein, in light of
     the circumstances under which they were made, not misleading; (ii) provide
     the Investor copies of any documents filed pursuant to this Section
     2.2(b)(i); and (iii) inform the Investor that the Company has complied with
     its obligations in this Section 2.2(b)(i) (or that, if the Company has
     filed a post-effective amendment to the Registration Statement which has
     not yet been declared effective, the Company will notify the Investor to
     that effect, will use commercially reasonable efforts to secure the

                                        9
<PAGE>

     effectiveness of such post-effective amendment as promptly as possible and
     will promptly notify the Investor pursuant to this Section 2.2(b)(i) when
     the amendment has become effective).

          (c) Subject to paragraph (d) below, in the event (i) of any request by
     the SEC or any other federal or state governmental authority during the
     period of effectiveness of the Registration Statement for amendments or
     supplements to a Registration Statement or related prospectus or for
     additional information; (ii) of the issuance by the SEC or any other
     federal or state governmental authority of any stop order suspending the
     effectiveness of a Registration Statement or the initiation of any
     proceedings for that purpose; (iii) of the receipt by the Company of any
     notification with respect to the suspension of the qualification or
     exemption from qualification of any of the Shares for sale in any
     jurisdiction or the initiation or threatening of any proceeding for such
     purpose; or (iv) of any event or circumstance which, upon the advice of its
     counsel, necessitates the making of any changes in the Registration
     Statement or prospectus, or any document incorporated or deemed to be
     incorporated therein by reference, so that, in the case of the Registration
     Statement, it will not contain any untrue statement of a material fact or
     any omission to state a material fact required to be stated therein or
     necessary to make the statements therein not misleading, and that in the
     case of the prospectus, it will not contain any untrue statement of a
     material fact or any omission to state a material fact required to be
     stated therein or necessary to make the statements therein, in the light of
     the circumstances under which they were made, not misleading; then the
     Company shall promptly deliver a certificate in writing to the Investor
     (the "Suspension Notice") to the effect of the foregoing and, upon receipt
     of such Suspension Notice, the Investor will refrain from selling any
     Shares pursuant to the Registration Statement (a "Suspension") until it
     receives copies of a supplemented or amended prospectus prepared and filed
     by the Company, or until it is advised in writing by the Company that the
     current prospectus may be used, and has received copies of any additional
     or supplemental filings that are incorporated or deemed incorporated by
     reference in any such prospectus. In the event of any Suspension, the
     Company will use its commercially reasonable efforts to cause the use of
     the prospectus so suspended to be resumed as soon as reasonably
     practicable.

          (d) Provided that a Suspension is not then in effect, the Investor may
     sell the Shares under the Registration Statement; provided, however, that
     it arranges for delivery of a current prospectus to the transferee of such
     Shares. Upon receipt of a request therefor, the Company has agreed to
     provide an adequate number of current prospectuses to the Investor and to
     supply copies to any other parties requiring such prospectuses.

          (e) In the event of a sale of the Shares by the Investor pursuant to
     the Registration Statement, the Investor must also deliver to the Company's
     transfer agent, with a copy to the Company, a Certificate of Subsequent
     Sale substantially in the form attached hereto as Exhibit A so that the
     Shares may be properly transferred. Assuming timely delivery to the
     Company's transfer agent of one or more stock certificates representing the
     Shares in proper form for transfer and assuming compliance by the Investor
     with the terms of this Deed, the Company's transfer agent will issue and
     make appropriate delivery of one or more stock certificates in the name of
     the buyer so as to permit timely compliance by the Investor with applicable
     settlement requirements.

     2.3  Indemnification.

          (a) Definitions.  For the purpose of this Section 2.3:

             (i) the term "Selling Stockholder" shall include the Investor and
        each person, if any, who controls the Investor within the meaning of
        Section 15 of the Securities Act, including any officer, director,
        trustee or Affiliate of the Investor;

             (ii) the term "Registration Statement" shall include any final
        prospectus, exhibit, supplement or amendment included in or relating to
        the Registration Statement referred to in Section 2.1; and

             (iii) the term "untrue statement" shall include any untrue
        statement or alleged untrue statement, or any omission or alleged
        omission to state in the Registration Statement a material

                                        10
<PAGE>

        fact required to be stated therein or necessary to make the statements
        therein, in the light of the circumstances under which they were made,
        not misleading.

          (b) Indemnification by the Company.  To the extent permitted by law,
     the Company agrees to indemnify and hold harmless the Selling Stockholder
     from and against any losses, claims, damages or liabilities to which such
     Selling Stockholder may become subject (under the Securities Act or
     otherwise) insofar as such losses, claims, damages or liabilities (or
     actions or proceedings in respect thereof) arise out of, or are based upon,
     (i) any untrue statement of a material fact contained in the Registration
     Statement, or (ii) any failure by the Company to fulfill any undertaking
     included in the Registration Statement, and the Company will reimburse such
     Selling Stockholder for any reasonable legal or other expenses reasonably
     incurred in investigating, defending or preparing to defend any such
     action, proceeding or claim; provided, however, that the Company shall not
     be liable in any such case to the extent that such loss, claim, damage or
     liability arises out of, or is based upon, an untrue statement made in such
     Registration Statement in reliance upon and in conformity with written
     information furnished to the Company by or on behalf of the Selling
     Stockholder specifically for use in preparation of the Registration
     Statement or the failure of the Selling Stockholder to comply with its
     covenants and agreements contained in the Deed respecting the sale of the
     Shares or any statement or omission in any prospectus that is corrected in
     any subsequent prospectus that was delivered to the Investor prior to the
     pertinent sale or sales by the Investor; provided however, that the Selling
     Stockholder shall be entitled to be indemnified in any such case for any
     statement or alleged statement in or omission or alleged omission from such
     Registration Statement, preliminary prospectus, final prospectus or summary
     prospectus contained therein, or any amendment or supplement thereto, in
     which such statement or omission has been corrected, in writing, by the
     Investor and delivered to the Company at least ten (10) days before the
     sale or sales from which such loss occurred. The Company shall reimburse
     the Selling Stockholder for the amounts provided for herein upon receipt of
     written demand providing evidence of such expenses.

          (c) Indemnification by the Investor. To the extent permitted by law,
     the Investor agrees to indemnify and hold harmless the Company (and each
     person, if any, who controls the Company within the meaning of Section 15
     of the Securities Act, each officer of the Company who signs the
     Registration Statement and each director of the Company) and all other
     selling stockholders listed in the Registration Statement from and against
     any losses, claims, damages or liabilities to which the Company (or any
     such officer, director or controlling person) may become subject (under the
     Securities Act or otherwise), insofar as such losses, claims, damages or
     liabilities (or actions or proceedings in respect thereof) arise out of, or
     are based upon, (i) any failure to comply with the covenants and agreements
     contained in this Deed respecting the sale of the Shares, or (ii) any
     untrue statement of a material fact contained in the Registration Statement
     if such untrue statement was made in reliance upon and in conformity with
     written information furnished by or on behalf of the Investor specifically
     for use in preparation of the Registration Statement, and the Investor will
     reimburse the Company (or such officer, director or controlling person), as
     the case may be, for any reasonable legal or other expenses reasonably
     incurred in investigating, defending or preparing to defend any such
     action, proceeding or claim; provided however, that the Selling Stockholder
     shall have no obligation to indemnify the Company in any such case for any
     statement or alleged statement in or omission or alleged omission from such
     Registration Statement, preliminary prospectus, final prospectus or summary
     prospectus contained therein, or any amendment or supplement thereto, in
     which such statement or omission has been corrected, in writing, by the
     Investor and delivered to the Company at least ten (10) days before the
     sale or sales from which such loss occurred. The Investor shall reimburse
     the Company and the other selling stockholders listed in the Registration
     Statement for the amounts provided for herein upon receipt of written
     demand providing evidence of such expenses.

          (d) Notice of Claims, Etc. Promptly after receipt by any indemnified
     person of a notice of a claim or the beginning of any action in respect of
     which indemnity is to be sought against an indemnifying person pursuant to
     this Section 2.3, such indemnified person shall notify the

                                        11
<PAGE>

     indemnifying person in writing of such claim or of the commencement of such
     action, but the omission to so notify the indemnifying party will not
     relieve it from any liability which it may have to any indemnified party
     under this Section 2.3 (except to the extent that such omission materially
     and adversely affects the indemnifying party's ability to defend such
     action) or from any liability otherwise than under this Section 2.3.
     Subject to the provisions hereinafter stated, in case any such action shall
     be brought against an indemnified person, the indemnifying person shall be
     entitled to participate therein, and, to the extent that it shall elect by
     written notice delivered to the indemnified party promptly after receiving
     the aforesaid notice from such indemnified party, shall be entitled to
     assume the defense thereof, with counsel reasonably satisfactory to such
     indemnified person. After notice from the indemnifying person to such
     indemnified person of its election to assume the defense thereof, such
     indemnifying person shall not be liable to such indemnified person for any
     legal expenses subsequently incurred by such indemnified person in
     connection with the defense thereof; provided, however, that if there
     exists or shall exist a conflict of interest that would make it
     inappropriate, in the opinion of counsel to the indemnified person, for the
     same counsel to represent both the indemnified person and such indemnifying
     person or any Affiliate or associate thereof, the indemnified person shall
     be entitled to retain its own counsel at the expense of such indemnifying
     person; provided, however, that no indemnifying person shall be responsible
     for the fees and expenses of more than one separate counsel (together with
     appropriate local counsel) for all indemnified parties. In no event shall
     any indemnifying person be liable in respect of any amounts paid in
     settlement of any action unless the indemnifying person shall have approved
     the terms of such settlement; provided, however, that such consent shall
     not be unreasonably withheld. No indemnifying person shall, without the
     prior written consent of the indemnified person, effect any settlement of
     any pending or threatened proceeding in respect of which any indemnified
     person is or could have been a party and indemnification could have been
     sought hereunder by such indemnified person, unless such settlement
     includes an unconditional release of such indemnified person from all
     liability on claims that are the subject matter of such proceeding.

          (e) Contribution. If the indemnification provided for in this Section
     2.3 is unavailable to or insufficient to hold harmless an indemnified party
     under paragraph (b) or (c) above in respect of any losses, claims, damages
     or liabilities (or actions or proceedings in respect thereof) referred to
     therein, then each indemnifying party shall contribute to the amount paid
     or payable by such indemnified party as a result of such losses, claims,
     damages or liabilities (or actions in respect thereof) in such proportion
     as is appropriate to reflect the relative fault of the Company on the one
     hand and the Investor, as well as any other selling stockholder under the
     Registration Statement, on the other in connection with the statements or
     omissions or other matters which resulted in such losses, claims, damages
     or liabilities (or actions in respect thereof), as well as any other
     relevant equitable considerations. The relative fault shall be determined
     by reference to, among other things, in the case of an untrue statement,
     whether the untrue statement relates to information supplied by the Company
     on the one hand or an Investor or other selling stockholder on the other
     and the parties' relative intent, knowledge, access to information and
     opportunity to correct or prevent such untrue statement. The Company and
     the Investor agree that it would not be just and equitable if contribution
     pursuant to this paragraph (e) were determined by pro rata allocation (even
     if the Investor and other selling stockholders were treated as one entity
     for such purpose) or by any other method of allocation which does not take
     into account the equitable considerations referred to above in this
     paragraph (e). The amount paid or payable by an indemnified party as a
     result of the losses, claims, damages or liabilities (or actions in respect
     thereof) referred to above in this paragraph (e) shall be deemed to include
     any legal or other expenses reasonably incurred by such indemnified party
     in connection with investigating or defending any such action or claim. No
     person guilty of fraudulent misrepresentation (within the meaning of
     Section 11(f) of the Securities Act) shall be entitled to contribution from
     any person who was not guilty of such fraudulent misrepresentation.

          (f) Survival.  The obligations of the Company and the Investor under
     this Section 2.3 shall survive the completion of any offering of Shares in
     a Registration Statement.

                                        12
<PAGE>

3 RULE 144.

     The Company covenants that it will file the reports required to be filed by
it under the Securities Act and the Exchange Act and the rules and regulations
adopted by the SEC thereunder (or, if the Company is not required to file such
reports, it will, upon the request of the Investor, make publicly available such
information as necessary to permit sales pursuant to Rule 144 under the
Securities Act), and it will take such further action as the Investor may
reasonably request, all to the extent required from time to time to enable the
Investor to sell the shares purchased hereunder without registration under the
Securities Act within the limitation of the exemptions provided by (a) Rule 144
under the Securities Act, as such rule may be amended from time to time, or (b)
any similar rule or regulation hereafter adopted by the SEC. Upon the request of
the Investor, the Company will deliver to it a written statement as to whether
the Company has complied with such information and requirements.

4 SUCCESSORS AND ASSIGNS.

     The rights set forth in this Annex A may not be assigned by the Investor.
Without the necessity of the prior written consent of the Investor, but after
notice duly given and in compliance with Clause 8 of the Deed, the Company may
assign its rights and delegate its duties hereunder to any successor-in-interest
corporation in the event of a merger or consolidation of the Company with or
into another corporation, or any merger or consolidation of another corporation
with or into the Company that results directly or indirectly in an aggregate
change in the ownership or control of more than 50% of the voting rights of the
equity securities of the company, or the sale of all or substantially all of the
Company's assets. The terms and conditions of this Annex shall inure to the
benefit of and be binding upon the respective permitted successors and assigns
of the parties. Nothing in this Annex A, express or implied, is intended to
confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under
or by reason of this Annex A, except as expressly provided in this Annex A.

                                        13
<PAGE>

                                   EXHIBIT A

                         Certificate of Subsequent Sale

Bank of New York
101 Barclay Street
New York, NY 10286

     RE: Sale of Shares of Common Stock of OSI Pharmaceuticals, Inc. (the
         "Company") pursuant to the Company's Prospectus dated           ,
         (the "Prospectus")

Dear Sir/Madam:

     The undersigned hereby certifies, in connection with the sale of shares of
Common Stock of the Company included in the table of Selling Stockholders in the
Prospectus, that the undersigned has sold the shares pursuant to the Prospectus
and in a manner described under the caption "Plan of Distribution" in the
Prospectus and that such sale complies with all applicable securities laws,
applicable to the undersigned, including, without limitation, the Prospectus
delivery requirements of the Securities Act of 1933, as amended.

Selling Stockholder (the beneficial owner):
-------------------------------------------------------------------

Record Holder (e.g., if held in name of nominee):
-----------------------------------------------------------

Restricted Stock Certificate No.(s):
---------------------------------------------------------------------------

Number of Shares Sold:
--------------------------------------------------------------------------------

Date of Sale:
--------------------------------------------------------------------------------

     In the event that you receive a stock certificate(s) representing more
shares of Common Stock than have been sold by the undersigned, then you should
return to the undersigned a newly issued certificate for such excess shares in
the name of the Record Holder and BEARING A RESTRICTIVE LEGEND. Further, you
should place a stop transfer on your records with regard to such certificate.

<Table>
<S>                                             <C>
                                                Very truly yours,

                                                By:
                                                --------------------------------------------
Dated:
--------------------------------------------
                                                Print Name:
                                                ----------------------------------------
                                                Title:
                                                --------------------------------------------
</Table>

cc:  Robert L. Van Nostrand
     Vice President and Chief Financial Officer
     OSI Pharmaceuticals, Inc.
     58 South Service Road, Suite 110
     Melville, NY 11747

                                        14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]